 |
|
Palifermin-Associated Papular Eruption
Brett King, MD, PhD;
Eleanor Knopp, MD;
Anjela Galan, MD;
Gerard Nuovo, MD;
Robert Tigelaar, MD;
Jennifer McNiff, MD
Arch Dermatol. 2009;145(2):179-182.
Background Palifermin is a recombinant human keratinocyte growth factor that is used to reduce the duration and severity of oral mucositis in patients undergoing hematopoietic stem cell transplantation after myelotoxic therapy. Cutaneous adverse reactions associated with keratinocyte growth factor are reported to be rash, pruritus, and erythema.
Observations After receiving palifermin following autologous hematopoietic stem cell transplantation and treatment with melphalan, a patient developed erythema and lichenoid papules that were distributed primarily in intertriginous areas. A biopsy specimen of the papules showed a striking resemblance to verrucae, but in situ hybridization studies were negative for human papillomavirus. Immunohistochemical staining with antibodies to Ki-67 and cytokeratin 5/6 showed increased keratinocyte proliferation in lesional skin.
Conclusions After treatment with palifermin, a papular eruption clinically resembling lichen planus or plane warts, with histologic features of verruca plana, and intertriginous erythema may occur. In this case, neither eruption required treatment, and spontaneous resolution was observed over days to weeks. Histopathologic staining patterns of Ki-67 and cytokeratin 5/6 may be useful in identifying adverse reactions to palifermin therapy.
Author Affiliations: Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut (Drs King, Knopp, Galan, Tigelaar, and McNiff); and Department of Pathology, Ohio State Medical Center, Columbus (Dr Nuovo).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
This Month in Archives of Dermatology
Arch Dermatol. 2009;145(2):119.
FULL TEXT
|
